XML 123 R40.htm IDEA: XBRL DOCUMENT v3.25.1
LICENSE AND DISTRIBUTION AGREEMENTS (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 16, 2024
USD ($)
Dec. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Jan. 24, 2022
USD ($)
LICENSE AGREEMENTS                
Revenue       $ 22,270,465   $ 25,178,066    
Deferred revenue, current   $ 12,000,000   12,000,000   24,270,465    
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Potential milestone payments   80,000,000   80,000,000        
Milestone payments to be made upon completion of certain phases   10,000,000   10,000,000   10,000,000    
Upfront payment             $ 30,000,000  
Revenue       22,300,000   25,200,000    
Deferred revenue, current           $ 12,300,000    
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan                
LICENSE AGREEMENTS                
Potential milestone payments     $ 89,000,000          
Upfront payment     $ 12,000,000          
Deferred revenue liability   12,000,000   12,000,000        
Deferred revenue, current   12,000,000   $ 12,000,000        
Binding Term Sheet With Nippon Shinyaku Co Limited Europe                
LICENSE AGREEMENTS                
Upfront payment $ 20,000,000              
Potential additional development and sales-based milestone payments $ 715,000,000              
Rome License Agreement                
LICENSE AGREEMENTS                
Notice period       90 days 90 days      
JHU License Agreement                
LICENSE AGREEMENTS                
Notice period       60 days 60 days      
Threshold period to cure breach       30 days 30 days      
CSMC License Agreement                
LICENSE AGREEMENTS                
Notice period       90 days 90 days      
Exosomes License Agreement                
LICENSE AGREEMENTS                
Notice period       90 days 90 days      
Minimum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Share of product revenue (in percent)               30.00%
Minimum | Rome License Agreement                
LICENSE AGREEMENTS                
Minimum annual royalty payments | €         € 20,000      
Maximum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Potential milestone payments               $ 605,000,000
Share of product revenue (in percent)               50.00%
Maximum | JHU License Agreement                
LICENSE AGREEMENTS                
Potential milestone payments   1,850,000   $ 1,850,000        
Completion Of Phase Three | JHU License Agreement                
LICENSE AGREEMENTS                
Milestone payments to be made upon completion of certain phases             500,000  
Obtention of FDA Approval | JHU License Agreement                
LICENSE AGREEMENTS                
Milestone payments to be made upon completion of certain phases             1,000,000  
Completion Of Phase Two Due | JHU License Agreement                
LICENSE AGREEMENTS                
Milestones paid             $ 250,000  
First Milestone Payment                
LICENSE AGREEMENTS                
Milestone payments to be made upon completion of certain phases   10,000,000   10,000,000        
First Milestone Payment | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Milestone payments to be made upon completion of certain phases   10,000,000   10,000,000        
Upfront payment       30,000,000        
First Milestone Payment | CSMC | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Recognized as revenue       40,000,000        
Deferred revenue liability   40,000,000   40,000,000        
Second Milestone Payment | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Milestones paid   10,000,000            
Upfront payment       30,000,000        
Deferred revenue, current   0   0        
Second Milestone Payment | CSMC | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Deferred revenue liability   50,000,000   50,000,000        
Development Milestone Payment, One | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Milestone payments to be made upon completion of certain phases   10,000,000   10,000,000        
Development Milestone Payment, Two | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States                
LICENSE AGREEMENTS                
Milestone payments to be made upon completion of certain phases   $ 10,000,000   $ 10,000,000        
Patent rights | JHU License Agreement                
LICENSE AGREEMENTS                
Agreement effective period       20 years 20 years      
Non Payment of Royalties | CSMC License Agreement                
LICENSE AGREEMENTS                
Agreement termination period       30 days 30 days      
Non Payment of Royalties | Exosomes License Agreement                
LICENSE AGREEMENTS                
Threshold period to cure breach       30 days 30 days      
CSMC Agreement Compliance | CSMC License Agreement                
LICENSE AGREEMENTS                
Agreement termination period       90 days 90 days      
CSMC Agreement Compliance | Exosomes License Agreement                
LICENSE AGREEMENTS                
Threshold period to cure breach       90 days 90 days      
Material Breach Has Not Been Cured | CSMC License Agreement                
LICENSE AGREEMENTS                
Agreement termination period       90 days 90 days      
Material Breach Has Not Been Cured | Exosomes License Agreement                
LICENSE AGREEMENTS                
Threshold period to cure breach       90 days 90 days      
Fails To Cure Breach after Notice From CSMC | CSMC License Agreement                
LICENSE AGREEMENTS                
Agreement termination period       90 days 90 days      
Fails To Cure Breach after Notice From CSMC | Exosomes License Agreement                
LICENSE AGREEMENTS                
Threshold period to cure breach       90 days 90 days